283 related articles for article (PubMed ID: 22818842)
1. Prognostic factors in pelvic exenteration for gynecological malignancies.
Baiocchi G; Guimaraes GC; Rosa Oliveira RA; Kumagai LY; Faloppa CC; Aguiar S; Begnami MD; Soares FA; Lopes A
Eur J Surg Oncol; 2012 Oct; 38(10):948-54. PubMed ID: 22818842
[TBL] [Abstract][Full Text] [Related]
2. Does histologic type correlate to outcome after pelvic exenteration for cervical and vaginal cancer?
Baiocchi G; Guimaraes GC; Faloppa CC; Kumagai LY; Oliveira RA; Begnami MD; Soares FA; Lopes A
Ann Surg Oncol; 2013 May; 20(5):1694-700. PubMed ID: 23212765
[TBL] [Abstract][Full Text] [Related]
3. Pelvic Exenteration for Advanced Nonrectal Pelvic Malignancy.
PelvExCollaborative
Ann Surg; 2019 Nov; 270(5):899-905. PubMed ID: 31634184
[TBL] [Abstract][Full Text] [Related]
4. Predictors for long-term survival after interdisciplinary salvage surgery for advanced or recurrent gynecologic cancers.
Fleisch MC; Pantke P; Beckmann MW; Schnuerch HG; Ackermann R; Grimm MO; Bender HG; Dall P
J Surg Oncol; 2007 May; 95(6):476-84. PubMed ID: 17192947
[TBL] [Abstract][Full Text] [Related]
5. Long-term clinical outcome of pelvic exenteration in patients with advanced gynecological malignancies.
Fotopoulou C; Neumann U; Kraetschell R; Schefold JC; Weidemann H; Lichtenegger W; Sehouli J
J Surg Oncol; 2010 May; 101(6):507-12. PubMed ID: 20401918
[TBL] [Abstract][Full Text] [Related]
6. Five-year experience with combined operative and radiotherapeutic treatment of recurrent gynecologic tumors infiltrating the pelvic wall.
Höckel M; Sclenger K; Hamm H; Knapstein PG; Hohenfellner R; Rösler HP
Cancer; 1996 May; 77(9):1918-33. PubMed ID: 8646694
[TBL] [Abstract][Full Text] [Related]
7. Total pelvic exenteration for primary and recurrent malignancies.
Ferenschild FT; Vermaas M; Verhoef C; Ansink AC; Kirkels WJ; Eggermont AM; de Wilt JH
World J Surg; 2009 Jul; 33(7):1502-8. PubMed ID: 19421811
[TBL] [Abstract][Full Text] [Related]
8. Pelvic exenteration for primary and recurrent gynaecological malignancies.
de Wilt JH; van Leeuwen DH; Logmans A; Verhoef C; Kirkels WJ; Vermaas M; Ansink AC
Eur J Obstet Gynecol Reprod Biol; 2007 Oct; 134(2):243-8. PubMed ID: 16950559
[TBL] [Abstract][Full Text] [Related]
9. Pelvic exenteration and sphincter preservation: an analysis of 96 cases.
Poletto AH; Lopes A; Carvalho AL; Ribeiro EA; Vieira RA; Rossi BM; Aguiar S; Guimarães GC; Ferreira Fde O; Nakagawa WT
J Surg Oncol; 2004 Jun; 86(3):122-7. PubMed ID: 15170649
[TBL] [Abstract][Full Text] [Related]
10. Mesorectal lymph node involvement and prognostic implications at total pelvic exenteration for gynecologic malignancies.
Mourton SM; Chi DS; Sonoda Y; Alektiar KM; Venkatraman ES; Barakat RR; Abu-Rustum NR
Gynecol Oncol; 2006 Mar; 100(3):533-6. PubMed ID: 16226800
[TBL] [Abstract][Full Text] [Related]
11. Pelvic exenteration: ten-year experience at the European Institute of Oncology in Milan.
Maggioni A; Roviglione G; Landoni F; Zanagnolo V; Peiretti M; Colombo N; Bocciolone L; Biffi R; Minig L; Morrow CP
Gynecol Oncol; 2009 Jul; 114(1):64-8. PubMed ID: 19411097
[TBL] [Abstract][Full Text] [Related]
12. Exenteration as a primary treatment for locally advanced cervical cancer: long-term results and prognostic factors.
Forner DM; Lampe B
Am J Obstet Gynecol; 2011 Aug; 205(2):148.e1-6. PubMed ID: 21640963
[TBL] [Abstract][Full Text] [Related]
13. Pelvic exenteration for gynecological malignancies: an analysis of 15 cases operated on at a single institution.
Mäenpää JU; Kangasniemi K; Luukkaala T
Acta Obstet Gynecol Scand; 2010; 89(2):279-83. PubMed ID: 19916881
[TBL] [Abstract][Full Text] [Related]
14. Indications for primary and secondary exenterations in patients with cervical cancer.
Marnitz S; Köhler C; Müller M; Behrens K; Hasenbein K; Schneider A
Gynecol Oncol; 2006 Dec; 103(3):1023-30. PubMed ID: 16890276
[TBL] [Abstract][Full Text] [Related]
15. Pelvic exenteration: long-term oncological results in a series of 106 patients.
De Wever I
Acta Chir Belg; 2011; 111(5):282-7. PubMed ID: 22191128
[TBL] [Abstract][Full Text] [Related]
16. Pelvic exenterations for gynecological malignancies: a study of 36 cases.
Kaur M; Joniau S; D'Hoore A; Van Calster B; Van Limbergen E; Leunen K; Penninckx F; Van Poppel H; Amant F; Vergote I
Int J Gynecol Cancer; 2012 Jun; 22(5):889-96. PubMed ID: 22617477
[TBL] [Abstract][Full Text] [Related]
17. Pelvic exenteration with curative intent for recurrent uterine malignancies.
Khoury-Collado F; Einstein MH; Bochner BH; Alektiar KM; Sonoda Y; Abu-Rustum NR; Brown CL; Gardner GJ; Barakat RR; Chi DS
Gynecol Oncol; 2012 Jan; 124(1):42-7. PubMed ID: 22014627
[TBL] [Abstract][Full Text] [Related]
18. Pelvic lymph node count is an important prognostic variable for FIGO stage I and II endometrial carcinoma with high-risk histology.
Lutman CV; Havrilesky LJ; Cragun JM; Secord AA; Calingaert B; Berchuck A; Clarke-Pearson DL; Soper JT
Gynecol Oncol; 2006 Jul; 102(1):92-7. PubMed ID: 16406063
[TBL] [Abstract][Full Text] [Related]
19. [Pelvic exenteration of advanced gynecological malignacies: a report of 18 cases].
Zhang Z; Zang R; Chen J
Zhonghua Fu Chan Ke Za Zhi; 2000 May; 35(5):288-90. PubMed ID: 11775910
[TBL] [Abstract][Full Text] [Related]
20. Pelvic exenteration, University of Michigan: 100 patients at 5 years.
Morley GW; Hopkins MP; Lindenauer SM; Roberts JA
Obstet Gynecol; 1989 Dec; 74(6):934-43. PubMed ID: 2586960
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
